Prostate cancer screening and the role of PSA: A UK perspective

REFERENCES

1. ↵
   1. Siegel RL,
   2. Miller KD,
   3. Jemal A

   . Cancer statistics, 2020. CA Cancer J Clin 2020; 70(1):7–30. doi:10.3322/caac.21590

   OpenUrlCrossRefPubMed
2. ↵
   1. Prostate Cancer UK

   . About prostate cancer. https://prostatecanceruk.org/prostate-information/about-prostate-cancer. Accessed November 30, 2020.
3. ↵
   1. Hugosson J,
   2. Roobol MJ,
   3. Mansson M,
   4. et al

   . A 16-yr follow-up of the European Randomised Study of Screening for Prostate Cancer. Eur Urol 2019; 76(1);45–51. doi:10.1016/j.eururo.2019.02.009

   OpenUrlCrossRef
4. ↵
   1. Pinsky PF,
   2. Prorok PC,
   3. Yu K,
   4. Kramer BS,
   5. Black A

   . Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer 2017; 123(4):592–599. doi:10.1002/cncr.30474

   OpenUrlCrossRefPubMed
5. ↵
   1. Hamdy FC,
   2. Donovan JL,
   3. Lane JA,
   4. et al

   . 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016; 375(15):1415–1424. doi:10.1056/NEJMoa1606220

   OpenUrlCrossRefPubMed
6. ↵
   1. Bryant RJ,
   2. Hobbs CP,
   3. Eyre KS,
   4. et al

   . Comparison of prostate biopsy with or without multiparametric magnetic resonance imaging for prostate cancer detection: an observational cohort study. J Urol 2019; 201(3):510–519. doi:10.1016/j.juro.2018.09.049

   OpenUrlCrossRef
7. ↵
   1. Kasivisvanathan V,
   2. Stabile A,
   3. Neves JB,
   4. et al

   . Magnetic resonance imaging-targeted biopsy versus systematic biopsy in the detection of prostate cancer: a systematic review and meta-analysis. Eur Urol 2019; 76(3):284–303. doi:10.1016/j.eururo.2019.04.043

   OpenUrlCrossRef
8. ↵
   1. Lilja H,
   2. Cronin AM,
   3. Dahlin A,
   4. et al

   . Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011; 117(6):1210–1219. doi:10.1002/cncr.25568

   OpenUrlCrossRefPubMed
9. ↵
   1. Sooriakumaran P

   . Smarter screening for prostate cancer: for the few, not the many? A stratified approach based on baseline risk. Expert Rev Anticancer Ther 2011; 11(2):169–172. doi:10.1586/era.10.233

   OpenUrlCrossRefPubMed